for our newsletter!
McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor. MMAF is a new auristatin derivative with a charged C-terminal phenylalanine that attenuates its cytotoxic activity compared to its uncharged counterpart, Monomethyl auristatin E (MMAE). Because of MMAF is highly toxic, it cannot be used as a drug itself. MMAF induces potent antitumor effects when conjugated via protease cleavable linkers to a monoclonal antibody targeting internalizing, tumor-specific cell surface antigens. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the anti-mitotic mechanism. Potential mode of action/Key words: Targeting Tubulin, Tubulin polymerization inhibitor, Cytotoxic
Toxins with Linkers
Cfm Oskar Tropitzsch GmbH also provides linker-drug conjugates. Either as linker-drug conjugate or under contract synthesis arrangements. To take advantage of this service please contact us email@example.com for more information. Some ...